<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04695366</url>
  </required_header>
  <id_info>
    <org_study_id>LyPRO1</org_study_id>
    <nct_id>NCT04695366</nct_id>
  </id_info>
  <brief_title>The Potential of Patient-reported Outcome Measures in Detection of Relapse in Diffuse Large B-cell Lymphoma</brief_title>
  <official_title>The Potential of Patient-reported Outcome Measures in Detection of Relapse in Diffuse Large B-cell Lymphoma - a Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Annually some 450 patients are diagnosed with Diffuse Large B-cell Lymphoma (DLBCL), in&#xD;
      Denmark. The majority of these patients are cured with immunochemotherapy, but up to 30 %&#xD;
      will relapse, pointing to the need for targeted surveillance and follow-up strategy. However,&#xD;
      this strategy is constantly under debate illustrated by the missing data supporting scheduled&#xD;
      face-to-face meetings with a clinician and routine surveillance scans in order to detect&#xD;
      relapse. On top of the clinical problems comes the psychological burden for patients enrolled&#xD;
      in routine surveillance. This points to the need for the development of evidence-based&#xD;
      follow-up programs both in terms of content, regularity and assignment of responsibility&#xD;
      between the health system and the patient. In a prospective cohort study, the investigators&#xD;
      will collect Patient Reported Outcome (PRO) measures investigating if questionnaires can be&#xD;
      used to detect relapse in DLBCL patients. Furthermore psychological aspects of follow-up are&#xD;
      explored.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the Western world, DLBCL is the most common subtype of non-Hodgkin lymphoma (NHL). In&#xD;
      Denmark, approximately 450 patients are diagnosed with DLBCL every year. Treatment with&#xD;
      anthracycline-based immunochemotherapy (most commonly rituximab, cyclophosphamide,&#xD;
      doxorubicin, vincristine and prednisone) is curative in the majority of DLBCL patients but a&#xD;
      significant number of patients (up to 30 %) do not achieve a complete response (CR), and an&#xD;
      additional subset of patients ultimately relapse after CR.&#xD;
&#xD;
      Second-line treatment with salvage chemotherapy followed by autologous hematopoietic cell&#xD;
      transplantation (auto-HCT) is potentially curative, therefore surveillance for relapse is&#xD;
      important.&#xD;
&#xD;
      Risk of relapse is declining after two years and for patients achieving event-free survival&#xD;
      for 24 months (post treatment), survival beyond this timepoint is close to equivalent to that&#xD;
      of the general population.&#xD;
&#xD;
      However optimal means of follow-up for patients with DLBCL remain controversial and have been&#xD;
      a somewhat overlooked and contentious issue.&#xD;
&#xD;
      Traditionally, routine follow-up in DLBCL patients consists of face-to-face meetings with a&#xD;
      specialist in an outpatient clinic, with varying intervals and a mixture of surveillance&#xD;
      components, such as clinical examinations, blood tests or imaging procedures.&#xD;
&#xD;
      To illustrate the lack of consistency in this patient group, the ESMO guidelines recommend&#xD;
      follow-up with 4 visits in the first year, every 6 months the next 2 years and then annually,&#xD;
      whereas The British Society of Hematology guidelines recommend clinical follow-up for 2 years&#xD;
      followed by discharge. Guidelines from the Danish Lymphoma Group (DLG) reflect the&#xD;
      recommendations outlined in the Lugano classification. Patients with International Prognostic&#xD;
      Index (IPI) 0-1 who have obtained complete remission (CR), are recommended to be followed&#xD;
      every 3 to 4 months the first year, then every 6 months for 2 years, without routine use of&#xD;
      image diagnostics. For patients with IPI&gt; = 2, clinical follow-up is recommended every 3 to 4&#xD;
      months the first 2 years, then every 6 months for 3 years. CT scan is used 6, 12 and 24&#xD;
      months after completion of treatment.&#xD;
&#xD;
      In recent years the value of post-therapy surveillance scans in DLBCL has been questioned.&#xD;
      Only a minority of relapses are detected solely via imaging and no survival advantage&#xD;
      associated with the use of surveillance imaging has been demonstrated.&#xD;
&#xD;
      Another argument against scheduled follow-up is, that the majority of relapses are probably&#xD;
      identified outside the scheduled follow-up visits, and by patients themselves rather than by&#xD;
      the physicians.&#xD;
&#xD;
      Patient-reported outcome (PRO) data is information reported through questionnaires, directly&#xD;
      by patients, about how they observe symptoms, physical function and quality of life. During&#xD;
      recent years, PRO has experienced much attention due to the increasing evidence of the&#xD;
      positive effect of clinical responses to PRO measures, that are applied as intervention aids&#xD;
      both in terms of relieving the symptom burden, improvements in the overall psychosocial&#xD;
      function of the patient and survival benefits in two studies. It has been argued that the use&#xD;
      of PRO offers an opportunity to facilitate a transition to a more patient centred approach by&#xD;
      strengthening the role of patients in observing themselves. But there are several barriers&#xD;
      for the implementation of PRO, such as accessibility, user-friendliness, processing the&#xD;
      collected information, difficulties for patients having few resources and finally the&#xD;
      interpretation of the PRO data.&#xD;
&#xD;
      To the investigator's knowledge, no study has investigated, if collection of PRO data is&#xD;
      useful in detection of relapse in DLBCL or other lymphoma subtypes. As of today, most studies&#xD;
      in this patient group have focused on HRQOL, late-effects or unmet needs in survivorship&#xD;
      after treatment of lymphoma.&#xD;
&#xD;
      To solve this dilemma between ineffective, scheduled follow-up visits and the constant need&#xD;
      for identifying patients at risk of relapse, it has been suggested, that PRO measures offer a&#xD;
      potential for use by clinicians as a decision aid in identifying patients in need for&#xD;
      clinical consultation.&#xD;
&#xD;
      Psychosocial distress (anxiety, fear and depressive feelings) have been described to be&#xD;
      significant in lymphoma survivors and associated to a more frequent use of Health Care&#xD;
      services. One explanation is that lymphoma survivors need for psychosocial support is not met&#xD;
      in the current follow-up program.&#xD;
&#xD;
      Another explanation, is that there may be a psychological burden to routine surveillance and&#xD;
      scheduled follow-up visits in the outpatient clinic. Anxiety symptoms, depressive feelings&#xD;
      and fear of recurrence (FCR) in long-term lymphoma survivors are especially prevalent in the&#xD;
      time leading up to surveillance scans.&#xD;
&#xD;
      A fear of relapse might be a rational response after treatment of a life-threatening disease,&#xD;
      but FCR have been associated to lower quality of life, increased psychological distress,&#xD;
      dissatisfaction with care, and severe FCR even with an inferior overall survival compared&#xD;
      with survivors without severe FCR.&#xD;
&#xD;
      Interestingly, it has been argued whether FCR is a consequence or a cause of anxiety,&#xD;
      depression and lower quality of life. Maybe cancer survivors with certain anxiety traits&#xD;
      and/or a tendency of negative views about their health and quality of life are more at risk&#xD;
      of experiencing FCR during their survivorship.&#xD;
&#xD;
      Socio-demographic data such as female gender, younger age, living alone or poor social&#xD;
      support have been associated with increased risk of FCR, but also poorer health conditions&#xD;
      and advanced cancer stage (26).&#xD;
&#xD;
      To the investigator's knowledge, no study has investigated the association between&#xD;
      socio-demographic data, comorbidities, health literacy and psychosocial distress during&#xD;
      follow-up of lymphoma patients. It offers the potential to identify patients in need of more&#xD;
      or less support during follow-up and to move in the direction of a more personalized care of&#xD;
      lymphoma patients.&#xD;
&#xD;
      The aim of the study is to create a PRO questionnaire and test feasibility and the potential&#xD;
      to detect relapse in DLBCL patients.&#xD;
&#xD;
      In addition, PRO data is collected on patient experiences during follow-up and psychological&#xD;
      aspect of survivorship.&#xD;
&#xD;
      The investigator's hope for the future is to move towards a more patient centred and&#xD;
      individualized follow-up after treatment of lymphoma patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 10, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between each item in the questionnaire or groups of items and subsequent relapse</measure>
    <time_frame>2 years</time_frame>
    <description>indicators of relapse.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of routine follow-up on psychological distress</measure>
    <time_frame>2 years</time_frame>
    <description>Changes in fear of recurrence questionnaire (FCRI-SF) and quality of life questionnaires (EORTC-QLQ-C30) around time of routine follow-up visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of personality on psychological distress</measure>
    <time_frame>2 years</time_frame>
    <description>Correlation between level of uncertainty intolerance (IUS questionnaire) and quality of life (EORTC-QLQ-C30) and fear of recurrence (FCRI-SF) and correlation between health literacy (44- item questionnaire) and quality of life (EORTC-QLQ-C30) and fear of recurrence (FCRI-SF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility testing of electronic use of questionnaires in DLBCL patients</measure>
    <time_frame>2 years</time_frame>
    <description>Patient compliance measured as patient satisfaction from a questionnaire and inclusion rate</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <condition>Patient Reported Outcome</condition>
  <arm_group>
    <arm_group_label>Diffuse large B-cell lymphoma patients in year 1 and 2 of clinical follow-up</arm_group_label>
    <description>Patients (Diffuse Large B-cell Lymphoma) in complete remission after primary treatment and entering the regular follow-up program at the clinic. Baseline is defined as date of end-of-treatment visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention</description>
    <arm_group_label>Diffuse large B-cell lymphoma patients in year 1 and 2 of clinical follow-up</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        From 1 January 2021 to 31 December 2022, we will invite all DLBCL patients in remission&#xD;
        after first-line curative treatment provided at the hematology departments of Herlev&#xD;
        hospital, Universtity of Copenhagen, and Rigshospitalet, University of Copenhagen, to&#xD;
        participate.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. DLBCL diagnosed according to the WHO classification&#xD;
&#xD;
          2. Age &gt;18 years at diagnosis&#xD;
&#xD;
          3. Completed curative intent first line treatment with anthracycline-containing&#xD;
             immuno-chemotherapy with or without consolidating radiotherapy and achieved CR on&#xD;
             end-of-treatment CT/PET-CT scan, as recorded in the medical record by the treating&#xD;
             physician.&#xD;
&#xD;
          4. Participated in less than 2 years of follow-up without biopsy-verified relapse&#xD;
&#xD;
          5. Access to electronic communication with health authorities (e-Boks - an electronic,&#xD;
             closed two factor authentication)&#xD;
&#xD;
          6. Able to receive an email and complete a questionnaire in Danish&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Verified lymphoma in the central nervous system (CNS)&#xD;
&#xD;
          2. Initial treatment not completed&#xD;
&#xD;
          3. CR not reached after initial treatment&#xD;
&#xD;
          4. Palliative treatment including attenuated chemotherapy&#xD;
&#xD;
          5. Undergoing anti-lymphoma treatment or treatment for other cancer.&#xD;
&#xD;
          6. Inability to read Danish or no access to electronic communication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Therese Lassen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Therese Lassen, MD</last_name>
    <phone>26715171</phone>
    <email>marie.therese.lassen.02@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lars M Pedersen, MD, PhD</last_name>
    <phone>38686527</phone>
    <email>lars.moeller.pedersen.01@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Therese Lassen</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Therese Lassen</last_name>
      <phone>26715171</phone>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 15, 2020</study_first_submitted>
  <study_first_submitted_qc>January 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2021</study_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Herlev Hospital</investigator_affiliation>
    <investigator_full_name>Lars MÃ¸ller Pedersen</investigator_full_name>
    <investigator_title>Chief Physician, Head of research, PhD, MD</investigator_title>
  </responsible_party>
  <keyword>follow-up</keyword>
  <keyword>surveillance</keyword>
  <keyword>feasibility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

